



AMENDMENT TRANSMITTAL LETTER

Atty. Docket No. HEBVR-5

Serial No. 09/123,620

filed 7/28/98

Examiner K.K. Fonda

Group Art Ubit 1614

In re. application of

Howard E. Elford; THERAPEUTIC PROCESS FOR INHIBITION OF NF- κ B

CLAIMS AS AMENDED

Total Claims = 11 pain for = 20 extra = 0 No additional

Indep Claims = 3 paid for = 3 extra = 0 fees.

James L. Rowe, Atty. for Applicant

Reg. No. 18'448

Dated:

7775 Spring Mill Rd.

11/15/99

Indianapolis IN 46260

Phone 317-251-0077



HF #81D
GP1614 12-16-99
Dhane
(NE)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Howard L. Elford

Serial No. 09/123,620

Filed: 7/28/98

Group Art Unit 1614

THERAPEUTIC PROCES FOR

Examiner K.K. Fonda

INHIBITING NF-KB

Commissioner of Patents and Trademarks

Washington DC 20231

Sir

RECEIVED

NOV 22 1999

TECH CENTER 1600/2900

RESPONSE TO FINAL REJECTION

In response to the Final Rejection of the Claims dated 9/23/99,
please amend the above-entitled application as follows.


IN THE SPECIFICATION

page 7, line 1 after "inflammation," insert "diabetes, a
tissue transplant, an organ transplant, a cell transplant,
arteriosclerosis,"

IN THE CLAIMS

Amend Claim 1 as follows:

1) A process for inhibiting NF- κ B in a mammalian cell in which
NF- κ B has been activated by an agency external to said cell
which comprises administering to the mammal in whose cells NF- κ B
has been activated an NF- κ B inhibiting amount of a drug
represented by the formula:



wherein n is 2-5, m is 0 or 1, R is NH₂, NHOH, OC₁₋₃ alkyl, or
O-phenyl, R' is O, NH or NOH, R'' is H or OH, acylated phenol
derivatives of said drugs, and pharmaceutically-acceptable
acid-addition salts [and acylated phenol derivatives] thereof.

to Not
ENTER
(2-23-99)
KMF